Irvin M. Modlin
Yale University
Internal medicineEndocrinologySurgeryPathologyOncologyMolecular biologyReceptorChemistryEnterochromaffin-like cellSomatostatinGastrinNeuroendocrine tumorsDiseaseRadionuclide therapySecretionCancer researchMedicineBiomarker (medicine)Chromogranin ABiologyEnterochromaffin cellGastroenterology
498Publications
81H-index
19.3kCitations
Publications 508
Newest
#1Irvin M. Modlin (Yale University)H-Index: 81
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 11 authors...
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (...
Source
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 3 authors...
Abstract null null The recent development of peptide receptor radionuclide therapy (PRRT) into an accepted treatment modality allows for consideration of what needs to be undertaken to move beyond the siege warfare concept of tumor therapy. This chapter therefore seeks to address and resolve the limitations of the “huff and puff” theory of tumor destruction by critically applying the concepts and knowledge of radionuclide therapy. It therefore discusses the advantages of PRRT without ignoring it...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 7 authors...
INTRODUCTION Identification of residual disease after neuroendocrine tumor (NET) resection is critical for management. Post-surgery imaging is insensitive, expensive and current biomarkers ineffective. We evaluated whether the NETest, a multigene liquid biopsy blood biomarker, correlated with surgical resection and could predict recurrence. METHODS Multicenter evaluation of NET resections over 24 months (n=103): 47 pancreas, 26 small bowel, 26 lung, 2 appendix, 1 duodenum, 1 stomach. Surgery: R0...
Source
Abstract Biomarkers that are secretory monoanalyte products of GEP (gastro-entero-pancreatic) and BP (broncho-pulmonary) or lung NETs (neuroendocrine tumors) have significant limitations in clinical utility. The assessment of secretory activity provides little information in regard to tumor biology. Furthermore, ∼50% of NETs have measurable secretory products. Molecular genomic identification in blood (NETest liquid biopsy) of the regulators of tumor biology provide multianalyte, real-time asses...
Source
Abstract In respect of Carcinoid disease, one might well ask – why have we failed so miserably? In 1907, Oberndorfer described “karzinoide” and yet more than a century later, most diagnoses still reflect incurable metastatic disease. Attempts to address the biology and mechanistic basis of NETs have lacked logic, balanced oversight or linearity. Governance appears directed to the support of countless clinical trials, often so underpowered and scientifically improbable as to seem based more on ma...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 17 authors...
Introduction Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. Methods This was a multicenter ev...
3 CitationsSource
78 null Introduction: null null Peptide receptor radionuclide therapy (PRRT) is effective in neuroendocrine tumor (NET) management but there are limited tools for monitoring (RECIST) and prediction of tumor response, and for the delineation of side-effects. Accurate monitoring of tumor response is constrained by post-PRRT imaging limitations, and there are no effective blood-genomic assays for hematologic toxicity. We utilized three independent blood-based gene expression assays: a 51-marker gen...
Source
#1Andrea Frilling (Imperial College London)H-Index: 19
#2Ashley K. Clift (Imperial College London)H-Index: 13
Last. Richard P. BaumH-Index: 63
view all 11 authors...
Rationale: Neuroendocrine neoplasia (NEN) of small bowel (SBNEN) frequently present with metastatic disease. Theranostics (molecular imaging followed by targeting therapy) allow for personalised medicine. Liquid biopsies enable precise identification of residual disease and real-time monitoring of therapeutic response. Our aim was to determine the clinical utility of a combination of surgery, theranostics, and a multigene blood measurement in metastasised SBNEN. Methods: Inclusion criteria were ...
1 CitationsSource
#1Anja Rinke (University of Marburg)H-Index: 22
#2Christoph J. Auernhammer (LMU: Ludwig Maximilian University of Munich)H-Index: 31
Last. Thomas M. Gress (University of Marburg)H-Index: 82
view all 14 authors...
Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic a...
1 CitationsSource